Lipid Accumulation Product is a Valid Predictor of Hepatic Steatosis and Nonalcoholic Fatty Liver Disease
Qiaoli Huang, Xuying Tan, Qiongmei Wu, Hanqing Zhao, Hangjun Chen, Xinxue Yu, Jinting Wang, Xueyi Huang, Yurong Huang, Jun Wei, Feng Wu, Huilian Zhu, Lijun Wang
Abstract
Aims: To evaluate and compare lipid accumulation product (LAP) with alanine aminotransferase (ALT), aspartate aminotransferase (AST), visceral adiposity index (VAI) and triglyceride-glucose index (TyG) as biomarkers for hepatic steatosis and nonalcoholic fatty liver disease (NAFLD). Methods: LAP, ALT, AST, VAI and TyG were measured in 52 biopsy-proven NAFLD patients and 21 control subjects. Additionally, LAP was also measured in 448 ultrasound-proven NAFLD patients and 1009 control subjects. Results: LAP was positively associated with hepatic steatosis and inflammation in biopsy-proven NAFLD. The risk of NAFLD was positively related to LAP and TyG, but LAP showed a better area under the receiver operating characteristic curve for hepatic steatosis and NAFLD. LAP also performed well in recognizing ultrasound-proven NAFLD. Conclusion: LAP is an ideal biomarker of hepatic steatosis and NAFLD.